Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Clinical trial NCT06376084 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06376084
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL

Carcinoma, Non-Small-Cell Lung Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms

Start date: 2024-07-23
Primary completion: 2028-02-28
Enrollment: 532

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.